Appendix I Appendix II

112 Pages·2017·10.5 MB·English

vasculitis in' border. of
VOLUME II
CONTENTS
TABLES
illustration3
AEPjNUICi^ i
Appendix I
Appendix II
T
A
B
L
E
S
TABLE 1: Clarification of Differentiated Muscle Cell and Pericyte
on E.M. Level
Cytoplasmic Differentiated Pericyte
Characteristics Muscle Cell
Cytoplasmic Aggregated in polar More diffusely
Organelles cytoplasm distributed
Cytoplasmic
myofibrils Present Absent
Long cytoplasmic
processes Absent Present
*^LDAl'
(
larutaN( FO 2
redroB
DL^IF dHT
LATOT AGa
esaesid DETCHFNI evitcefni toH LAMINA
detaluconI
)noitcefni oiiihAC DNi^
detaluconi
klAGBAiii
SUTATG
)tnega
muluconi
hfivv
LaTNj
-non
* +
= = AUTaT
nI sdiK
ni( FO
tcatnoc
)detroba daeD liT
7 7 - -gnidule
j
AO
OF
ybLaMIIAl
htiw BUT/ OA i'.L'x
A
86 53 42 )dellik( 7
eht 9 eviL BUT-ATO
olfILUoJn
ojLIoGIT
detcefni
6 6 lluF( TA
+ + NI FO
nrobllitJ
3 — 3 - ,m
k X GNILPMB ii>-:JiiOB IICIIG.
.slamina ;mret
adliG
evil ju.j.jI;;
3 3 retfa(daeD BMAL
+ + — mm
ivLBALltiVA
1 1 ]htrib
*
031 911
)dellik(eviL NO
+ 3 + 4 4
+'~3 3 ;..L.il,i
+
+
* £ *
■ .{.OF
■
■ LATOT
■ 071
— 82 51 i^KT
922
3 ++3+
LAj>t.A-+l)iA-"Oli
*21
"
TABLE 3 The nature and the number of tissues examined and the
results of vasculitis in the susceptible group.
No. positive/ No. examined
TISSUES
80-120 days
Gestation Neonatal
Brain 10/23 2/2
Spinal Cord 6/24 1/1
Sciatic Nerve 2/21 mm
Spleen 0/20 -
Lymph Node 1/20
Liver 0/21 -
Lung 1/23 -
Kidney 1/24 -
Testes 0/l 0/2
Epididymis 0/1 1/2
Adipose tissue* 4/22 -
Pineal Body 0/1 mm
Thyroid 0/1 mm
Thymus 0/1 mm
Adrenal Gland 0/1 -
* In the vicinity of lymph node and kidney
- No tissue available for the study.
TABLE 4 The distribution of post-inoculations at sampling and
its effect on the results of vasculitis.
Post-inoculation at No. positive/
sampling in days No. studied
18 0/1
21 M1
26-27 2/2
35 0/1
41 0/2
47 1/4
49-51 2/3
52-53 2/3
54-55 3/6
56-57 1/2
180 1/1
TaiiLiS 5 Class of Progeny available for the study
cGNsrOL INPACTAD
Groups Groups TOTAL
Ciiiibs OF PROCANY "A" "B" "B" 11,V>tt
FOdfUoCb
Bead 1 3 1 2 7
*
Alive 16+1 27 + 2 21 67
L/ilBo
stillborn 1 1
Dead 1 1
Alive 2 15 17
GRAND TOTAL 93
* Sharing with group "B"
N.B. Two dead infected foetuses were later discarded due to putrifaction.
TABLA 6 Ratio of Nembutal to Heparin use in Foetuses
jiteaiaL Ms toblital Q<1'/- Heparan Ul^i) Total Volume (mis.)
105 0.25 4.75 5
115 0.50 5.00 5.5
125 0.75 6.00 6.75
155 1.00 7.00 8.00
142 1.00 7.00 8.00
TABLgj 7 Volume of the perfusate and needle gauge used for perfusion
according to the age of foetus
Age of Foetus Needle Gauge Perfusate
days mis.
55 - 65 18 500 - 550
65 - 75 18 600 - 650
75 - 85 16 700 - 750
£0 1 cn 16 800 - 850
95 - 105 13 900 - 950
105 - 115 13 1000 - 1050
125 - 142 13 1100 - 1250
TABLci 8 Distribution of the vasculitis in the infected groups
of progeny in relation to the age at inoculation
i
No. positive, for vasculitis/No. examined
groups
AGd at inoculation "A" "3" "c"
0/2*
50 0/28 + 0/1
60 0/2 0/2
70 0/3 0/0
80 0/1 0/1
90 0/1 1/3
100 0/3 0/2
110 0/3 2/3
120 1/4 0/3
150 0/2 1/2
* Sharing with Group "B"
N.B. 1. One foetus of Group A at gestational age of 50 and a
lamb of Group C from 120 days inoculate were dead.
2. Another lamb from 120 days of inoculation in Group G
was still-born.
2. All of the Controls and two putrefied dead foetuses
of Group A are excluded from the Table.
2.Oh:. 9 Distribution of the vasculitis in the infected groups of progeny
in relation to the duration of pout-inoculation at sampling.
No. positive for vasculitis / No. examined
Age at inoculation in days
•ration of pout-inoculation
sampling in days 50 60 70 80 90 100 1 10 120 130
5 0/2
10 0/2
15-17 0/3 0/2 0/3 0/1 0/1 0/3 0/3 1/ 0/2
20 0/2
25 0/2
54 - 36 0/2 1/2
44 - 46 0/3 0/2
55 - 59 0/6 2/3
65 68 0/2 0/2
-
75 - 78 0/3 ¥ 1/2
85 0/2
91 92 0/2 0/1
-
103 - 109 0/2
116 0/1
237 o/i 1
li.B. One foetus of gestational age of 50 sampled 85 days later and
a lamb of group "C" from 120 days inoculate sampled 44 days post-
inoculation were dead.
The lamb sampled 17 days post-inoculation from 120 days inoculate
of group "0" was stillDorn.
All of the controls and two putrefied dead foetuses of group "A"
are excluded from he Table,
nikS atroA gnuL hpmyL neelpS sumyhT dioryhT ditoraP eyB yratiutiP citaics esopidA lanipS saercnaP traeH yrammaM niarB SSaLC ,tLBAT
* + kO 01
sedoN droc
fo dnalg dnalg evren +eussit dnalG SIT
esopidA
AUJ
yrammam morf dna
ecnedicnI
eht
eussit spuorg
.dnalg ssalc
fo
o
"B"
fo
eht sitilucsav
dna
eht
yrehpirep "C"
.oM
deiduts
31/0 41/0 41/0 41/0 41/0 41/0 41/0 01/0 41/0 01/0 41/0 41/0 41/0 41/0 41/0 3/0 41/1 "B" si ni
evitisoP
itPUORG
fo .detneserp noitaler
seussit
eht 41/0 41/0 41/0 41/0 41/0 41/0 41/0 31/0 41/0 01/0 41/0 41/1 41/1 31/1 31/1 3/1 41/4 f\lM-.I♦
/
yendik .oS ot
ni
eht
eht
72/0 82/0 82/0 82/0 82/0 82/0 82/0 32/0 82/0 02/0 82/0 82/1 82/1 72/1 72/1 6/1 82/5 latc'i denimaxe
dna
ssalc
egnar
hpmyl
mutceR muceaC muelI munedouD musamooA musamO muluciteR nemuR lanerdA yranirU yendiK etatsorP setseT suretU yravO llaG reviL fo ox'
SSALG
edon
seussit
reddalb elbitpecsus
dna
PO
dna dnalg reddalb
ni
SUSSIT
eht simydidipG
gnidnecsed
ega
lautca
031-03(
yrammam
,redro
)syad
o/o o/o 0/0 0/0 0/0 o/o 0/0 o/o 41/0 41/0 31/0 3/0 11/0 3/0 3/0 41/0 41/0 "3" SPUORG[
.dnalg
osla
ta
eht
41/0 41/0 41/0 31/0 31/0 41/0 41/0 41/0 41/0 21/0 31/o 7/0 3/0 6/0 6/C 31/0 31/0 "C" noitaluconi
srebmun
latoT
41/0 41/0 41/0 31/0 31/0 41/0 41/o 41/0 32/0 62/0 62/0 51/0 91/0 9/0 9/0 72/0 72/0
TABLiii 11 Details of the assessments of the optimum CNS block in
relation to the vasculitis in descending order in
positive examined cases.
Levels of CNC blocks No. positive/Ho. examined.
ft
B2 Corpus callosum at the back of transverse
fissure, internal capsule 8/18
B4fe Occipital poles, including hippocampus 8/l8
C7 Cervical enlargement of spinal cord 5/18
B1 Jfrontal pole 4/18
B5* Pons 4/18
B7* Medulla 3/18
B6 dagittal section of cerebellum 2/18
L3 Lumbar enlargement of spinal cord 2/18
*
B2 Including amygdaloid lobe, corpus callosum,
fornix, internal and external capsule 1/18
C2 Second cervical of 3pinal cord 1/18
T8 Kighth thoracic segment of spinal cord 1/18
* cf. Fig. 22